The sentinel node negative axilla: is it a no-go zone?

Abstract:

:The technique of sentinel node biopsy (SNB) presents a great opportunity to reduce the morbidity of surgical treatment of breast cancer. Using either dye, isotope or a combination, after completing a learning process a sensitivity of 80-99% may be achieved. Most surgeons would aim for a sensitivity of 95% but this will mean that 5% of patients will be under-staged, with disease within the axilla and possibly inappropriate advice with regard to adjuvant systemic therapy. Injudicious use of sentinel biopsy will lead to more local relapses and may diminish or neutralize gains from systemic therapy.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Fentiman IS,Mansel RE

doi

10.1053/ctrv.2002.0251

keywords:

subject

Has Abstract

pub_date

2002-02-01 00:00:00

pages

1-3

issue

1

eissn

0305-7372

issn

1532-1967

pii

S0305737202902513

journal_volume

28

pub_type

杂志文章
  • Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.

    abstract::Two regimens were tested, CHAP I and CHAP II, the latter, a hexamethylmelamine dosage-intensive regimen, first as second line (salvage) therapy and then as primary therapy. Both produced the most successful results achieved in the Mount Sinai series up to the time of their introduction, when compared to their predeces...

    journal_title:Cancer treatment reviews

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0305-7372(91)90025-u

    authors: Bruckner HW,Cohen C,Mandeli J,Chesser MR,Kabakow B,Wallach R,Holland J

    更新日期:1991-03-01 00:00:00

  • Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

    abstract::Thirty-one patients with metastatic renal cell carcinoma were seen at the Centre Léon Bérard from October 1987 to October 1988. According to our protocol, 11 were excluded leaving 20 in the study. The median age was 55 years (range 36 to 79 years). The median number of metastases was 9 (range 2 to 29) and the median n...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(89)90028-5

    authors: Philip T,Mercatello A,Negrier S,Philip I,Rebattu P,Kaemmerlin P,Gaspard M,Tognier E,Combaret V,Bijmann JT

    更新日期:1989-06-01 00:00:00

  • Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review.

    abstract::Bone-seeking radionuclides, such as Sr-89, Sm-153, and Re-186, have been shown to have an effect on pain from bone metastasis in prostate cancer. The effect on bone pain in other cancer types, including breast cancer, remains unclear. The purpose of the study was to perform a systematic review of the use of radioisoto...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,随机对照试验,评审

    doi:10.1016/j.ctrv.2011.05.008

    authors: Christensen MH,Petersen LJ

    更新日期:2012-04-01 00:00:00

  • Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

    abstract::Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers. Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients. Despite overexpress...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.001

    authors: Ocaña A,Amir E

    更新日期:2009-12-01 00:00:00

  • Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

    abstract::Lung cancer has the highest frequency of brain dissemination compared to all other solid tumours. Classical treatment options such as brain irradiation have started to be questioned due to lack of survival benefit and risk for severe side effects. Oncogenic driven tumours have the highest frequency of brain disseminat...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.02.004

    authors: Tsakonas G,De Petris L,Ekman S

    更新日期:2017-03-01 00:00:00

  • Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

    abstract::When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.007

    authors: Chargari C,Kirov KM,Bollet MA,Magné N,Védrine L,Cremades S,Beuzeboc P,Fourquet A,Kirova YM

    更新日期:2011-06-01 00:00:00

  • Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.

    abstract::Breast cancer is the most common malignancy in women worldwide, with a relatively high proportion of patients experiencing resistance to standard treatments. Cellular immunotherapy (CI), which is based on the extraction, modification, and re-infusion of the patient's immune cells, is showing promising results in these...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102089

    authors: Venetis K,Invernizzi M,Sajjadi E,Curigliano G,Fusco N

    更新日期:2020-11-01 00:00:00

  • Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.

    abstract::Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers and remains a challenge in oncology. In 1997, gemcitabine became the standard of care in metastatic setting. In the last decades, despite a number of clinical trials assessing novel cytotoxic agents and cell signaling inhibitors, overall sur...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.10.002

    authors: El Maalouf G,Le Tourneau C,Batty GN,Faivre S,Raymond E

    更新日期:2009-04-01 00:00:00

  • Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

    abstract::Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00079-3

    authors: Cusack JC

    更新日期:2003-05-01 00:00:00

  • Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

    abstract::The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer treatment. Despite the excellent disease control with initial EGFR TKI therapy, acquired resistance is ubiquitous and remains a key chal...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.02.006

    authors: Lim SM,Syn NL,Cho BC,Soo RA

    更新日期:2018-04-01 00:00:00

  • Early diagnosis and surgical management of prostate cancer.

    abstract::Prostate cancer is a significant cause of morbidity and mortality in the United States and Europe. The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00096-3

    authors: Linton KD,Hamdy FC

    更新日期:2003-06-01 00:00:00

  • p53 as a target for the treatment of cancer.

    abstract::TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.004

    authors: Duffy MJ,Synnott NC,McGowan PM,Crown J,O'Connor D,Gallagher WM

    更新日期:2014-12-01 00:00:00

  • Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

    abstract::Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite these advances, radiological complete response to therapy is rare. We meta-analyzed the incidence of complete response in patients treated with AAs and in controls in main randomized clinical trials for first-line therapy in meta...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2013.09.003

    authors: Iacovelli R,Alesini D,Palazzo A,Trenta P,Santoni M,De Marchis L,Cascinu S,Naso G,Cortesi E

    更新日期:2014-03-01 00:00:00

  • Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review.

    abstract:BACKGROUND AND AIMS:The use of oral anticancer drugs has increased in modern oncology treatment. The move from intravenous treatments towards oral anticancer drugs has increased the patients' own responsibility to take oral anticancer drugs as being prescribed. High rates of non-adherence to oral anticancer drugs have ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.12.014

    authors: Verbrugghe M,Verhaeghe S,Lauwaert K,Beeckman D,Van Hecke A

    更新日期:2013-10-01 00:00:00

  • Molecular targeted therapy of glioblastoma.

    abstract::Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposur...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.101896

    authors: Le Rhun E,Preusser M,Roth P,Reardon DA,van den Bent M,Wen P,Reifenberger G,Weller M

    更新日期:2019-11-01 00:00:00

  • Maintenance chemotherapy for non-small-cell lung cancer.

    abstract::Currently, platinum-based combination chemotherapy is the standard first-line chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based chemotherapy has been recommended for up to six cycles even for responders, and second-line chemotherapy has been considered when disease progression is confir...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.12.007

    authors: Kim YH,Mishima M

    更新日期:2011-11-01 00:00:00

  • Participation of adolescents with cancer in clinical trials.

    abstract::Adolescent patients with cancer reside in a "no-man's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older patients, adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.11.005

    authors: Ferrari A,Bleyer A

    更新日期:2007-11-01 00:00:00

  • Cancer surgery: the last 25 years.

    abstract::Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 历史文章,杂志文章,评审

    doi:10.1053/ctrv.1999.0147

    authors: Bremers AJ,Rutgers EJ,van de Velde CJ

    更新日期:1999-12-01 00:00:00

  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.

    abstract::Neoadjuvant chemotherapy (NAC) for breast cancer is evolving and subsequent adjuvant systemic treatment is mainly based on the presence of the Estrogen (ER) receptor, Progesterone (PR) receptor and Human Epidermal growth factor Receptor 2 (HER2) status on the core needle biopsy prior to treatment. It is not well known...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.11.006

    authors: van de Ven S,Smit VT,Dekker TJ,Nortier JW,Kroep JR

    更新日期:2011-10-01 00:00:00

  • Rectal and colon cancer: Not just a different anatomic site.

    abstract::Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.007

    authors: Tamas K,Walenkamp AM,de Vries EG,van Vugt MA,Beets-Tan RG,van Etten B,de Groot DJ,Hospers GA

    更新日期:2015-09-01 00:00:00

  • Gender and survival in malignant tumours.

    abstract:BACKGROUND:Epidemiological evidence supports the existence of a survival advantage for female patients with melanoma. This survival advantage often persists when other prognostic variables are taken into account. The basis for this female advantage or male disadvantage is not established although female sex steroids ca...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0220

    authors: Molife R,Lorigan P,MacNeil S

    更新日期:2001-08-01 00:00:00

  • Pediatric sarcomas and related tumors of the head and neck.

    abstract::Sarcomas of the head and neck region are a rare group of tumors in children and present challenges with regard to evaluation and treatment. Rhabdomyosarcomas are the most common sarcomas of the head and neck in children. Presence of metastases and complete surgical resectability continue to be the most relevant clinic...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.005

    authors: Huh WW,Fitzgerald N,Mahajan A,Sturgis EM,Beverly Raney R,Anderson PM

    更新日期:2011-10-01 00:00:00

  • Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

    abstract:BACKGROUND:Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.07.011

    authors: Sargos P,Baumann BC,Eapen L,Christodouleas J,Bahl A,Murthy V,Efstathiou J,Fonteyne V,Ballas L,Zaghloul M,Roubaud G,Orré M,Larré S

    更新日期:2018-11-01 00:00:00

  • Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.

    abstract::Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumour types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC). This agent has a generally favourable safety profile, and may be suitable for use in special populations s...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.12.008

    authors: Mano M

    更新日期:2006-04-01 00:00:00

  • Current questions for the treatment of advanced gastric cancer.

    abstract:BACKGROUND:Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in ad...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.09.007

    authors: Cervantes A,Roda D,Tarazona N,Roselló S,Pérez-Fidalgo JA

    更新日期:2013-02-01 00:00:00

  • Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.

    abstract::Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer. We identified 25 pre-clinical cell models ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.01.009

    authors: Stordal B,Pavlakis N,Davey R

    更新日期:2007-06-01 00:00:00

  • Megestrol acetate: clinical experience.

    abstract::The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), endometrial hyperplasia, benign prostatic hypertrophy, contraception, anorexia, cachexia and weight loss is reviewed, concluding with a toxicity pro...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0305-7372(89)90004-2

    authors: Schacter L,Rozencweig M,Canetta R,Kelley S,Nicaise C,Smaldone L

    更新日期:1989-03-01 00:00:00

  • Metastatic colorectal cancer.

    abstract::Metastatic colorectal cancer remains a public-health issue on a global scale. With development of a new generation of cytotoxic agents, survival has improved for patients with metastatic disease. How to maximize the benefit of chemotherapy with acceptable toxicity remains incompletely answered. Hepatic resection can p...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.07.005

    authors: Saletti P,Cavalli F

    更新日期:2006-11-01 00:00:00

  • Pancreatic cancer: current and future treatment strategies.

    abstract::Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.02.005

    authors: Pliarchopoulou K,Pectasides D

    更新日期:2009-08-01 00:00:00